PCSK9 inhibitors are medicines used to lower LDL cholesterol, often called bad cholesterol, and reduce the risk of heart attacks and strokes in certain people. They are particularly useful for people with very high cholesterol, inherited cholesterol disorders, or existing cardiovascular disease who need additional cholesterol control. These medicines are usually given as injections and may be prescribed alone or alongside other cholesterol-lowering treatments.
What Does PCSK9 Inhibitor Mean?
PCSK9 stands for proprotein convertase subtilisin/kexin type 9. It is a protein made mainly in the liver that helps control the number of LDL receptors on liver cells.
LDL receptors are small structures on liver cells that remove LDL cholesterol from the bloodstream. They attach to LDL particles and help the liver take them out of circulation.
The PCSK9 protein causes some of these receptors to break down. When fewer LDL receptors are available, the liver cannot remove LDL cholesterol as efficiently, allowing more of it to remain in the blood.
PCSK9 inhibitors block this process or reduce the production of the PCSK9 protein. This allows more LDL receptors to remain available, helping the liver remove more LDL cholesterol from the bloodstream.
What Are PCSK9 Inhibitors Used For?
PCSK9 inhibitors are primarily used to manage high LDL cholesterol and lower cardiovascular risk in people who meet specific treatment criteria. Healthcare professionals may consider these medicines in several situations.
1. High LDL Cholesterol That Remains Elevated
Some people continue to have high LDL cholesterol despite taking cholesterol-lowering medicines, such as statins, at appropriate doses. Others may not achieve the desired cholesterol reduction with their current treatment plan.
In these situations, a healthcare professional may consider adding a PCSK9 inhibitor to improve LDL cholesterol control. The decision depends on the person's cholesterol levels, cardiovascular risk, medical history, and response to existing treatment.
According to Cleveland Clinic, these medicines may be prescribed when cholesterol remains high despite other treatments.
2. Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is an inherited condition that causes unusually high LDL cholesterol levels. People with this condition may have elevated cholesterol from childhood, even when they follow healthy lifestyle habits.
There are two main forms:
- Heterozygous familial hypercholesterolemia (HeFH): This occurs when a person inherits an affected cholesterol-related gene from one parent.
- Homozygous familial hypercholesterolemia (HoFH): This is a rarer and generally more severe form in which an affected gene is inherited from both parents.
PCSK9 inhibitors can help lower LDL cholesterol in eligible people with familial hypercholesterolemia. They may be used alongside statins and other cholesterol-lowering medicines, depending on the individual's needs.
The National Library of Medicine's MedlinePlus explains that PCSK9 inhibitors may be used with statins in people with familial hypercholesterolemia or a high risk of cardiovascular complications.
3. Existing Cardiovascular Disease
People with established cardiovascular disease may have an increased risk of another cardiovascular event. This can include people with a history of heart attack, stroke, or certain other conditions affecting the heart and blood vessels.
Lowering LDL cholesterol can help reduce this risk. A healthcare professional may prescribe a PCSK9 inhibitor when additional cholesterol reduction is needed as part of a broader cardiovascular prevention plan.
For example, evolocumab is approved in the United States to reduce the risk of certain major cardiovascular events in eligible adults. The US Food and Drug Administration (FDA) prescribing information for Repatha describes its approved cardiovascular and cholesterol-lowering uses.
4. When Other Cholesterol Medicines Are Not Suitable
Some people cannot tolerate statins because of side effects or other medical considerations. Others may need additional treatment because their cholesterol remains above the level recommended for their cardiovascular risk.
Depending on the circumstances, a healthcare professional may consider a PCSK9 inhibitor when other treatment options are unsuitable or do not provide enough LDL cholesterol reduction.
These medicines are not automatically the first choice for everyone with high cholesterol. The treatment decision depends on the person's overall health, risk of cardiovascular disease, previous medication response, and treatment goals.
How Do PCSK9 Inhibitors Work?
PCSK9 inhibitors help the liver remove more LDL cholesterol from the blood by increasing the availability of LDL receptors.
The process can be understood in three steps:
- PCSK9 affects LDL receptors: The PCSK9 protein attaches to LDL receptors and promotes their breakdown.
- The medicine blocks or reduces PCSK9: Different PCSK9-targeting medicines either block the protein's activity or reduce the production of the protein.
- More LDL receptors remain available: The liver can remove more LDL cholesterol from the bloodstream.
This mechanism helps explain why PCSK9-targeting medicines can produce substantial reductions in LDL cholesterol. They work differently from statins, which reduce cholesterol production in the liver.
What Are the Different Types of PCSK9 Inhibitors?
PCSK9-targeting treatments include injectable monoclonal antibodies and a medicine that uses a different genetic mechanism to reduce PCSK9 production.
1. Alirocumab (Praluent)
Alirocumab is a monoclonal antibody that blocks the PCSK9 protein. This helps preserve LDL receptors and allows the liver to remove more LDL cholesterol.
It is used to lower cholesterol in eligible people and may also help reduce the risk of certain cardiovascular events. It is administered as an injection under the skin, generally every two or four weeks, depending on the prescribed dose.
The MedlinePlus drug information for alirocumab provides details about its uses, administration, and precautions.
2. Evolocumab (Repatha)
Evolocumab is another monoclonal antibody that blocks PCSK9 activity. It helps lower LDL cholesterol by allowing more LDL receptors to remain available on liver cells.
It is used for certain people with high cholesterol, including those with familial hypercholesterolemia. It is also approved for reducing the risk of specified cardiovascular events in eligible patients.
Evolocumab is administered under the skin. Depending on the treatment plan, it may be given every two weeks or once monthly.
3. Inclisiran (Leqvio)
Inclisiran is a PCSK9-targeting medicine, but it works differently from alirocumab and evolocumab. Instead of directly blocking the PCSK9 protein, it uses small interfering RNA (siRNA) technology to reduce the production of PCSK9 in liver cells.
By reducing PCSK9 production, inclisiran helps maintain more LDL receptors and lower LDL cholesterol.
It is administered by a healthcare professional as an injection under the skin. The usual schedule involves an initial dose, another dose three months later, and then doses every six months.
According to MedlinePlus information about inclisiran, this medicine is used to reduce LDL cholesterol and is administered at a healthcare facility.
How Effective Are PCSK9 Inhibitors at Lowering Cholesterol?
PCSK9 inhibitors can produce substantial reductions in LDL cholesterol. The exact response depends on the medicine, dose, other cholesterol treatments, and the individual's medical circumstances.
Monoclonal antibody medicines such as alirocumab and evolocumab can reduce LDL cholesterol considerably, including when added to other cholesterol-lowering medicines.
Inclisiran also lowers LDL cholesterol through its effect on PCSK9 production. Its longer dosing interval can be helpful for people who prefer fewer injections throughout the year.
The main purpose of these medicines is to achieve better cholesterol control. For eligible people with cardiovascular disease, some PCSK9 inhibitors also have evidence and approved indications for reducing cardiovascular events.
How Are PCSK9 Inhibitors Given?
Most PCSK9-targeting treatments are administered as injections under the skin, also called subcutaneous injections. The injection may be given in the abdomen, thigh, or upper arm, depending on the specific medicine and product instructions.
The dosing schedule differs between medicines:
- Alirocumab: Usually administered every two or four weeks.
- Evolocumab: Usually administered every two weeks or once monthly.
- Inclisiran: Given initially, repeated after three months, and then administered every six months.
Some products can be administered at home after appropriate instructions, while inclisiran is administered by a healthcare professional. The exact schedule and method should follow the prescribed treatment plan.
Can PCSK9 Inhibitors Be Taken With Statins?
Yes. PCSK9 inhibitors can be prescribed alongside statins when additional LDL cholesterol reduction is needed.
Statins reduce cholesterol production in the liver, while PCSK9 inhibitors help preserve LDL receptors that remove cholesterol from the bloodstream. Because they work through different mechanisms, combining them can provide additional cholesterol-lowering effects.
Some people may also receive other cholesterol medicines, such as ezetimibe, depending on their treatment needs.
However, not everyone needs combination treatment. A healthcare professional determines the appropriate medicines based on cholesterol results, cardiovascular risk, tolerability, and treatment response.
What Are the Possible Side Effects of PCSK9 Inhibitors?
Many people tolerate PCSK9-targeting medicines well, but side effects can occur. The specific effects depend on the medicine being used.
Possible side effects include:
- Injection-site reactions: Redness, swelling, itching, tenderness, or pain where the injection is given.
- Cold-like symptoms: Some people experience a runny nose, sore throat, or flu-like symptoms.
- Back pain: Back discomfort has been reported with some of these medicines.
- Joint or muscle discomfort: Some people experience muscle pain or soreness.
- Allergic reactions: Rarely, serious allergic reactions can occur.
Seek urgent medical attention if an injection is followed by signs of a serious allergic reaction, such as difficulty breathing, swelling of the face or throat, or widespread hives.
Before starting treatment, patients should tell their healthcare professional about previous medication allergies, pregnancy, plans for pregnancy, breastfeeding, and other medicines they use.
Who May Not Need a PCSK9 Inhibitor?
PCSK9 inhibitors are not necessary for most people with mildly or moderately elevated cholesterol. Many people can manage their cholesterol with lifestyle changes and other medicines, depending on their cardiovascular risk.
A healthcare professional may first consider:
- Dietary changes that support healthy cholesterol levels.
- Regular physical activity.
- Statins or other standard cholesterol-lowering medicines.
- Additional medicines, such as ezetimibe, when appropriate.
PCSK9 inhibitors may become an option when these approaches do not provide sufficient cholesterol reduction or when a person has a specific condition that makes additional treatment necessary.
How Do Doctors Decide Whether Someone Needs a PCSK9 Inhibitor?
The decision is based on more than a single cholesterol result. Healthcare professionals consider several factors to understand whether the expected benefits of treatment outweigh its potential risks and costs.
These factors may include:
- LDL cholesterol levels: Current results and the amount of reduction achieved with existing medicines.
- Cardiovascular history: Previous heart attacks, strokes, or established cardiovascular disease.
- Inherited cholesterol disorders: Whether familial hypercholesterolemia is present.
- Previous treatments: Whether statins and other cholesterol medicines have worked or caused unwanted effects.
- Overall cardiovascular risk: Other health conditions and factors that may increase the likelihood of cardiovascular problems.
- Individual treatment preferences: Injection schedules, affordability, access, and willingness to continue long-term treatment.
Blood tests are used to monitor LDL cholesterol and assess the response after treatment begins. Follow-up appointments help determine whether the treatment plan needs adjustment.
Are PCSK9 Inhibitors a Long-Term Treatment?
PCSK9 inhibitors may be used as long-term treatment when a person continues to need additional cholesterol reduction. High cholesterol and inherited cholesterol disorders often require ongoing management.
Stopping treatment may allow LDL cholesterol levels to rise again. The timing and extent of this change depend on the medicine and individual circumstances.
Patients should not stop or change their medication schedule without discussing it with their healthcare professional.
Key Takeaways About PCSK9 Inhibitors
PCSK9 inhibitors are advanced cholesterol-lowering medicines that help the liver remove more LDL cholesterol from the bloodstream. They are particularly useful for selected people with familial hypercholesterolemia, persistently high LDL cholesterol, or established cardiovascular disease who need additional treatment.
Alirocumab and evolocumab block the PCSK9 protein, while inclisiran reduces its production. Although these medicines can provide substantial LDL cholesterol reductions, they are not required for everyone with high cholesterol.
The choice of treatment depends on cholesterol levels, cardiovascular risk, previous treatment response, and individual medical needs. Regular follow-up helps ensure that treatment remains appropriate and effective.